adebrelimab

Home
Ligands
adebrelimab

GtoPdb Ligand ID: 13085

Synonyms: Arelili® | Ariely® | HTI-1088 | HTI1088 | SHR-1316 | SHR1316

adebrelimab is an approved drug (China NMPA (2023))

Compound class: Synthetic organic

Comment: Adebrelimab (SHR-1316; HTI-1088) is a chimeric humanized IgG4κ anti-PD-L1 monoclonal antibody.

References
1. Li J, Zhang D, Liu Z, Wang Y, Li X, Wang Z, Liang G, Yuan X, Li Y, Komorowski AL et al.. (2023) The combined effect and mechanism of antiangiogenic drugs and PD-L1 inhibitor on cell apoptosis in triple negative breast cancer. Ann Transl Med, 11 (2): 83. [PMID:36819490]
2. Mu L, Song Y, Zhao K, Liu Y, Fan Q, Wang X, Li Q, Wang X, Huang J. (2021) SHR-1316, an anti-PD-L1 antibody, plus chemotherapy as the first-line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study. Thorac Cancer, 12 (9): 1373-1381. [PMID:33760397]
3. Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, Xu X, Li X, Xu F, Fang Y et al.. (2022) Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol, 23 (6): 739-747. [PMID:35576956]

References

1. Li J, Zhang D, Liu Z, Wang Y, Li X, Wang Z, Liang G, Yuan X, Li Y, Komorowski AL et al.. (2023)
The combined effect and mechanism of antiangiogenic drugs and PD-L1 inhibitor on cell apoptosis in triple negative breast cancer.
Ann Transl Med, 11 (2): 83. [PMID:36819490]

2. Mu L, Song Y, Zhao K, Liu Y, Fan Q, Wang X, Li Q, Wang X, Huang J. (2021)
SHR-1316, an anti-PD-L1 antibody, plus chemotherapy as the first-line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study.
Thorac Cancer, 12 (9): 1373-1381. [PMID:33760397]

3. Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, Xu X, Li X, Xu F, Fang Y et al.. (2022)
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol, 23 (6): 739-747. [PMID:35576956]